Johnson & Johnson’s Remicade Patent Invalidated
The Patent and Trademark Office sends notice rejection of the company’s Remicade patent.
Johnson & Johnson announced on Feb. 12, 2015 that the company had received a notice of further action from the United States Patent and Trademark Office (PTO) that PTO re-examined and rejected US Patent No. 6,284,471 (‘471) relating to Remicade (infliximab). The company has 60 days to respond to PTO. J&J stated in a press release that the patent, which expires in September 2018, is valid and the company will appeal the rejection.
A revocation of the patent could be good news for Hospira’s biosimilar Inflectra (infliximab), which is approved for use in Central and Eastern Europe and just received approval for use in West Europe. Celltrion, a partner of Hospira, also has a biosimilar version of infliximab, Remsima, which is currently being reviewed for use in the United States by FDA.
Source: Johnson & Johnson
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
